| Date | Title | Description |
| 25.01.2026 | Mendra Revolutionizes Rare Disease Therapy with $82M AI-Driven Launch | Mendra, a San Francisco biopharmaceutical firm, launched with an oversubscribed $82 million Series A funding round. This capital infusion propels its mission. Mendra focuses on rare disease therapies. The company leverages advanced AI. It t... |
| 23.01.2026 | Mendra Launched With $82 Million Series A To Build AI-Enabled Rare Disease Therapeutics Portfolio | Mendra, a newly launched biopharmaceutical company focused on rare diseases, has closed an oversubscribed $82 million Series A to acquire, develop, and commercialize therapies targeting high-unmet-need indications. The financing was co-led ... |
| 23.01.2026 | Mendra Raises $82M in Series A Funding | Mendra, a San Francisco, CA-based biopharmaceutical company developing therapies for rare disease medicines, raised $82M in Series A funding.
The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Win... |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
Mon, Jan 12, 2026 13:00 CET Report this content
EQT Life Sciences invests in U.S.-based Kinaset Thera... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding.
The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 26.09.2025 | Ensoma Secures $53M to Accelerate In Vivo Stem Cell Gene Therapies | Ensoma has secured $53 million in a pivotal funding round. This capital infusion accelerates its groundbreaking work in one-time, in vivo stem cell therapies. A primary goal involves progressing the Phase 1/2 clinical trial for EN-374, spec... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding.
Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 23.09.2025 | Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact | Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previ... |
| 30.07.2025 | MapLight: $372.5 Million Series D Funding Raised For Developing Therapeutics For Central Nervous System | MapLight Therapeutics announced a $372.5 million oversubscribed Series D financing, co-led by Forbion and Goldman Sachs Alternatives, with participation from Sanofi, T. Rowe Price, Avego BioScience, and existing investors like Novo Holdings... |
| 28.07.2025 | MapLight Therapeutics Raises $372.5M in Series D Funding | MapLight Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $372.5M in Series D financing.
The round was led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional... |
| 28.07.2025 | Forbion Co-Leads $372.5 Million Series D Financing in MapLight Therapeutics | • One of the largest private biotech financings of 2025, following Forbion-backed Verdiva
• MapLight Therapeutics is the sixth private investment made from the Forbion Growth III Fund
Naarden, The Netherlands, July 28, 2025 – Forbion, a lea... |
| 22.07.2025 | Hailo launches Hailo-10H chip with support for generative AI at the edge
Join theCUBE Alumni Trust Network
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Artificial intelligence chip startup Hailo Technologies Ltd. today announced the commercial release of the Hailo-10H, its second-generation AI accelerator featuring powerful generative AI capabilities.
The Hailo-10H introduces new on-device... |
| 15.07.2025 | Fellow Health Raises $24M in Series B | Fellow Health, a San Leandro, CA-based company focused on advancing male reproductive health through patient-centric testing solutions, raised $24M in Series B funding.
The round was led by 5AM Ventures, with new participation from The Fore... |
| 10.07.2025 | Renasant Bio Raises $54.5M in Seed Funding | Renasant Bio, a Berkeley, CA-based developer of disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), raised $54.5M in Seed funding.
The round was led by 5AM Ventures, alongside other life sciences investors... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases |
GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 27.07.2024 | TMRW Life Sciences: Pioneering the Future of Fertility Storage | In the realm of fertility treatments, the stakes are high. The management of frozen sperm, eggs, and embryos is not just a technical task; it’s a matter of life and hope. TMRW Life Sciences is stepping into this arena with a bold vision and... |
| 25.07.2024 | TMRW Life Sciences: Automated Specimen Management Company Secures Over $28 Million In Series D | TMRW Life Sciences (TMRW), the creator of the only FDA-cleared automated specimen management and storage platform for frozen human sperm, eggs, and embryos, announced that it closed a $28+ million Series D equity funding round to meet high ... |
| 24.07.2024 | TMRW Life Sciences Exceeds Series D Financing Goal To Meet Soaring Demand from Fertility Clinics Seeking Safe & More Accurate Cryostorage Solutions | Financing Led by 5AM Ventures with Participation from FIOS Venture Holdings, DF Investment Partners, Transformation Capital, Life Sciences Innovation Fund, Casdin Capital & Others
Leading Women's Health Investors & Advocates Include... |
| 01.07.2024 | RareCyte: $20 Million Raised To Expand Orion Spatial Biology Platform | RareCyte, a life sciences company offering advanced Precision Biology platforms, including instruments, reagents, software, and services, announced the completion of $20 million in funding from new and existing investors. New investor Fores... |
| 23.05.2024 | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube -->
In mid-May, the ten V... |
| 03.05.2024 | Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost | Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI... |
| 02.05.2024 | Karius Raises $100M in Series C Funding | Karius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding.
The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n... |
| 02.05.2024 | Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test | What You Should Know:
– Karius®, a leader in genomic diagnostics for infectious disease, announced today the closing of a $100 million Series C funding round.
– Co-led by Khosla Ventures and newcomers 5AM Ventures and Gilde Healthcare, the ... |
| 14.11.2023 | Nouscom raises CHF65 million in oversubscribed Series C financing round | |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 07.04.2022 | A-Rod-backed sports betting app Mojo wants to let you bet on athletes like stocks | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Good morning, Term Sheeters. Jackson Fordyce here, filling in for Jessica.
Paid Content How North... |
| 06.04.2022 | Rough biotech market won't stop 5AM Ventures' new $750M life science funds | It’s a good time to be 5AM Ventures—and, evidently, a biotech looking for funding. The firm just closed two life science funds totaling $750 million even as the biotech sector as a whole struggles to gain its feet in a tumultuous market.
De... |
| 04.04.2022 | 5AM Ventures Closes $750 Million Across Two Life Science Funds and Announces Team Additions | - |
| 12.11.2021 | GycoEra seals series A financing round at CHF 45 million | |
| 17.05.2021 | Soteria Biotherapeutics : Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures | SAN FRANCISCO, May 17, 2021 /PRNewswire/ -- Soteria Biotherapeutics, Inc. ("Soteria"), a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients wi... |
| 19.12.2019 | RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing | SEATTLE, Dec. 19, 2019 /PRNewswire/ — RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M fi... |
| 17.12.2019 | TMRW Life Sciences Raises $25 Million in Series B Funding Led by 5AM Ventures | - |
| 17.12.2019 | TMRW Life Sciences Raises $25 Million In Series B Funding Led By 5AM Ventures | TMRW Life Sciences, creator of ivfOS, an integrated platform for automated, software-guided embryology and cryo-management, announced today it has closed $25 million in Series B funding led by 5AM Ventures. This recent funding brings total ... |
| 14.02.2019 | Term Sheet — Thursday, February 14 | THE KEY TO A BETTER PARTNERSHIP
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Well, turns out there is at least one thing (that we thought of).
We asked a number of venture inv... |
| 14.02.2019 | 5AM Venture Management Closes Two New Funds, Totaling $497M | 5AM Venture Management, LLC, a San Francisco, CA and Boston, MA-based life science venture capital firm, closed two new funds, totaling $497m in committed capital.
The funds include:
– 5AM Ventures VI, L.P., a $350m venture capital fund foc... |
| 13.02.2019 | 5AM Ventures Closes Two Life Science Venture Capital Funds | 5AM Venture Management, LLC (5AM) of San Francisco, CA and Boston, MA is pleased to announce the closing of two new venture capital funds, totaling $497 million in committed capital. The capital was raised from a broad range of institutiona... |
| 13.02.2019 | 5AM raises nearly $500M in two new biotech venture funds | According to Oct. 4, 2018 filings with the Securities and Exchange Commission, the total $350 million amount raised for 5AM Ventures VI is consistent with what the firm had sought to raise when it opened the fund. The filings for the Opport... |
| 08.10.2018 | Term Sheet — Monday, October 8 | THREE THINGS
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
In a matter of eight years, Green has turned Forerunner into one of the most successful early stage funds in Silicon Valley. I... |
| 09.08.2018 | Akouos Raises $50M to Advance Precision Medicine for Hearing Disorders | Akouos, a Boston, MA-based precision genetic medicine company developing gene therapies that restore and preserve hearing has raised $50 million in Series A funding co-led by 5AM Ventures and New Enterprise Associates (NEA) with participati... |
| 25.06.2018 | 5AM Ventures Leads $40M Series A for NodThera | Cambridge, UK - NodThera, a biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, today announces it has closed its Seri... |
| 03.01.2018 | 5AM Ventures Joins $55.3M Series A for Expansion Therapeutics | SAN DIEGO--(BUSINESS WIRE)--Expansion Therapeutics, Inc., a new 5AM Ventures formed private company focused on the discovery and development of ribonucleic acid (RNA) targeted small molecule medicines, announced today the close of a $55.3 m... |
| 19.12.2017 | Amy Burroughs Joins 5AM Ventures as Executive-in-residence | Amy Burroughs has joined 5AM Ventures as executive-in-residence, according to a press release. The firm is based in San Francisco and Boston and invests in life science companies, according to its website. Burroughs’ previous roles include ... |
| 18.12.2017 | Term Sheet — Monday, December 18 | UBER DRAMA
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
If these allegations are proven true, it could result in regulatory sanctions, fines, and further criminal investigations. Not exact... |
| 06.11.2017 | 5AM Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 16.05.2017 | SCIENTIST.COM RAISED $24 MILLION IN EQUITY FINANCING CO-LED BY LEERINK TRANSFORMATION PARTNERS AND 5AM VENTURES. | - |
| 27.02.2017 | 16 early-stage healthtech startups you need to know | From online marketplaces to wearables for mothers, these are the fastest-growing healthtech startups
Editor's note: Our Splash Health, Wellness and Wearables event is coming up on March 23 in San Francisco. We'll have Mario Schlosser (Found... |
| 31.01.2017 | 5AM Ventures Joins $65M Series C for Kinestral Technologies | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kinestral Technologies, Inc., developer of Halio™, the world’s most responsive smart-tinting glass, today announced that the company has closed a $65 million Series C equity funding round. The f... |
| 06.12.2016 | NeuroPharma Raises $36M Series C from 5AM Ventures | SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments for central nervous (CNS) disorders, today announced that it has closed a Series C ... |
| 03.12.2016 | Impel NeuroPharma raises $36M for drug delivery platform that bypasses blood-brain barrier | Impel NeuroPharma co-founder and CEO John Hoekman. (Impel NeuroPharma Photo)
Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and an accompanyi... |
| 23.10.2016 | 5AM Adds Principal, Venture Partner and CFO to Staff | 5AM Venture Management LLC of Menlo Park and Boston is pleased to announce the addition of the following three members to the firm:
David Allison, Ph.D. has joined as Principal,
Joe Victor has joined as Venture Partner, and
Rebecca Lucia, C... |
| 23.10.2016 | 5AM Adds Principal, Venture Partner and CFO to Staff | 5AM Venture Management LLC of Menlo Park and Boston is pleased to announce the addition of the following three members to the firm:
David Allison, Ph.D. has joined as Principal,
Joe Victor has joined as Venture Partner, and
Rebecca Lucia, C... |
| 08.09.2016 | Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | The wearable also has a “crave” button users can press that records the moment they want a cigarette and triggers an immediate coaching message through the app to help the user get through the moment without smoking.
There is also a behavio... |
| 31.05.2016 | 5AM VENTURES RAISES $285 MILLION LIFE SCIENCE VENTURE CAPITAL FUND | - |
| 30.05.2016 | 5AM Ventures has raised $285M for fifth fund (Updated) | Update On Monday, it confirmed the amount in a press release on its website.
In a phone interview with 5AM Founder and Managing Partner Andrew Schwab he confirmed that 5AM Ventures V would be similar to 5 AM Ventures IV. Its investment targ... |
| 30.05.2016 | Life Sciences Venture Capital Firm 5AM Ventures Closes Latest Fund, at $285M | Life sciences venture capital firm 5AM Ventures closed its latest fund, at $285m.
According to a regulatory form filed with the SEC, 80 unnamed investors participated in the offering of 5AM Ventures V, L.P..
The document lists Managing Part... |
| 17.05.2016 | PURIGEN BIOSYSTEMS RECEIVES $18.2M IN SERIES A FINANCING LED BY 5AM VENTURES AND ROCHE VENTURE FUND | - |
| 09.03.2016 | Daily funding roundup - March 9, 2016 | Catalyst DevWorks raised $11.5M; Omnes led investment in Intersec; Drive Spotter secured $750k
Drive Spotter, a video analytics platform for commercial fleets, secured $750,000 in seed financing led by Grinnell Mutual Reinsurance Company wi... |
| 03.02.2016 | Pear Therapeutics raises $20M for digital therapeutics portfolio aimed at substance abuse, schizophrenia | In a pivotal randomized trial, 399 patients seeking treatment for SUD related to cocaine, alcohol, cannabis, and stimulants across 10 treatment centers received either face-to-face therapy or reSET instead of therapist time. It claims that ... |
| 06.01.2016 | 5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M | “A fundamental question in stem cell biology is what determines the self-renewal and pluripotency of stem cells,” Gregory writes on his website. He points out RNAi’s role in these processes – and that his lab’s identified certain miRNAs tha... |
| 05.01.2016 | Daily funding roundup - January 5, 2016 | PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M
Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me... |
| 30.12.2015 | Solstice Biologics raises $4M – but where did CEO Lou Tartaglia go? | But Lou Tartaglia, a former partner at Boston-based Third Rock Ventures with a long history in successful startup launch, joined Solstice in June 2014 – an indication that the broader investment community stood behind the company’s RNAi sci... |
| 21.10.2015 | Daily funding roundup - October 21, 2015` | Arvinas bagged $41.6M; Clavis Insight received $20M; Adjust landed $17M
LeanTaaS, a Silicon Valley healthcare SaaS provider, today announced its first institutional funding round of $3 million led by Sedgwick Claims Management Services, Inc... |
| 19.03.2015 | Pear Therapeutics Closed Financing Round | Pear Therapeutics, a Boston, MA- and San Francisco, CA-based creator of prescription pharmaceutical-software combination products called eFormulations, closed on additional financing of undisclosed amount.
The round was led by 5AM Ventures,... |
| 19.03.2015 | West Coast Biotech Roundup: Juno, Nektar, Kite, Glooko & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Out west this week, Bay Area clinical data carried the day. Nektar got bad news from a Phase 3 breast cancer trial, but Pharmacyclics, about to become (a very expensive) part ... |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 12.06.2014 | Chrono raises $32M to develop its 'stop smoking' bracelet | Chrono Therapeutics‘ wearable, called SmartStop, injects a tiny bit of nicotine into the wearer’s bloodstream at timed intervals.
In this way it’s similar to the patch, but SmartStop gives the wearer some control over when that happens. Tim... |
| 04.12.2013 | Healthcare VC on the rebound? 5AM Ventures quickly raises its biggest fund yet | And there’s a reason for that. This year, 5AM portfolio companies Incline Therapeutics and Pearl Therapeutics were snatched up by The Medicines Company and AstraZeneca, respectively. Relypsa and KaloBios also both went public.
Amid a boom o... |
| 03.12.2013 | 5AM VENTURES RAISES $250 MILLION LIFE SCIENCE VENTURE CAPITAL FUND | - |
| 15.11.2012 | California pharma start-up targeting COPD & asthma using inhalers raises $65M | The money will be used to start a Phase 3 clinical trial for PT003, the company’s lead candidate to treat COPD.
“Through our comprehensive Phase 2 program, Pearl has characterized the dose response, minimally effective dose and optimal dose... |
| 13.11.2012 | Pearl Therapeutics Raises $65M Series D |
REDWOOD CITY, CA, 5AM Ventures, Clarus Ventures and New Leaf Venture Partners participated in the Series D round, which was led by Vatera Healthcare Partners.
>> Click here for more funding data on Pearl Therapeutics
>> To e... |
| 13.11.2012 | Pearl Therapeutics Raises $65M in Series D Financing | Pearl Therapeutics Inc., a Redwood City, CA-based biopharmaceuticals company, has raised $65m in Series D financing.
The round was led by Vatera Healthcare Partners, with participation from existing investors 5AM Ventures, Clarus Ventures a... |
| 24.08.2012 | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | Osvaldo (Lalo) Flores, the president and chief scientific officer of Novira Therapeutics in Radnor, Pennsylvania, told MedCity News in a phone interview that the biotechnology company’s capsid-targeting antivirals entering preclinical devel... |
| 11.10.2011 | Cleave Biosciences Raises $42M in Series A Financing | Cleave Biosciences, a Burlingame, California-based newly established biopharmaceutical company discovering and developing novel therapies for cancer, has raised $42m in Series A financing.
Investors include U.S. Venture Partners, 5AM Ventur... |
| 19.10.2010 | Pearl Therapeutics Closes $69M Series C Financing | Pearl Therapeutics Inc., a Redwood City, CA-based company that develops clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COP... |
| 07.12.2009 | 5AM VENTURES RAISES $200M FOR 3RD LIFE SCIENCE VENTURE CAPITAL FUND | - |
| 16.10.2009 | Flexion Therapeutics Raises $33M in Series A Financing | Flexion Therapeutics, a Woburn, Mass.-based company that advances drug candidates through clinically meaningful proof of concept and beyond, completed a $33m Series A financing round led by Versant Ventures with participation from founding ... |
| 27.04.2009 | TivaMed culls $6M more for stealthy gynecology device | TivaMed, a medical device maker working on radio-frequency-based technology for the gynecology field, has raised another $6 million in a first round of funding — bringing the total of the round to $10 million. Based in Palo Alto, Calif., th... |
| 23.03.2009 | 5AM Ventures closes $119M for third life science fund | 5AM Ventures , a Menlo Park, Calif. venture firm specializing in seed or early-stage life science and biopharmaceutical investments, announced that it’s raised $119.25 million toward a third fund of at least $150 million. The money came fro... |
| 23.03.2009 | 5AM Ventures raises $119 million for life science, biopharma fund | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 11.03.2009 | Heart drug co. Relypsa gets $10M more to complete trials | Pharmaceutical company Relypsa announced that its investors extended its first round of funding by $10 million to a total $43 million to help it finish phase-two clinical trials on its lead drug candidate, a treatment that could alleviate s... |
| 24.02.2009 | Pearl Therapeutics gathers $8M to treat breathing disorders | Pearl Therapeutics, a Redwood City, Calif.-based developer of inhaled drugs to treat respiratory diseases like COPD and asthma, just landed $8 million in venture debt from Oxford Finance and Silicon Valley Bank to expand its product line.
T... |
| 07.01.2009 | Anaphore cultures $25M for protein treatments | Biotech firm Anaphore has raised $25 million in first-round funding to continue development of protein therapies for cancer and immune diseases. The money, which includes $8 million in seed financing received in March, is enough to push a c... |
| 03.07.2008 | Pearl Therapeutics ups its first round funding | Pearl Therapeutics, a biopharmaceutical company, has upped its first round of funding to $33.5 million after an additional $18 million investment, according to VentureWire.
New investor Nektar Therapeutics joins all of the company’s previou... |
| 21.03.2008 | ImmunoNewco: The background story emerges | Just over six weeks ago, we broke the news that 5AM Ventures had plunked $3.3 million into a stealthy biotech it was calling ImmunoNewco, and a few weeks later speculated further that the startup might be engaged in a pharmacogenomic “rescu... |
| 31.01.2008 | 5AM Ventures’ stealthy $3.3M, immune-related startup | (UPDATED: See below.)
5AM Ventures has invested $3.3 million in an immunology startup so far known only as ImmunoNewco. Andy Schwab, a co-founder of 5AM, confirmed the investment but declined to provide further details, saying only that “we... |
| 24.07.2007 | KaloBios draws in $20M for antibody drugs | KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its l... |
| 16.05.2007 | Marcadia Biotech pulls in $15M for hypoglycemia drug | Marcadia Biotech, an Indianapolis biotech focused on diabetes and obesity, raised $15 million in a first round of funding led by Frazier Healthcare Ventures and founding investor 5AM Ventures. Founding investor Twilight Venture Partners als... |
| 05.01.2007 | 5AM Ventures raises $150M venture fund, its second | 5AM Ventures, a Menlo Park health care firm, has raised its second venture fund at $150 million and has already funded three companies from it, Managing Partner Andrew J. Schwab told VentureWire (sub required).
VentureBeat VentureBeat's mis... |
| - | Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | Smoking cessation is a big priority for self-insured employer programs and payers, particularly since most payers are inclined to reimburse for these programs because of the impact of smoking on health. The challenge, as Chrono Therapeutics... |
| - | Pear Therapeutics raises $20M for digital therapeutics portfolio aimed at substance abuse, schizophrenia | A therapeutics company that pairs a digital health component with therapeutics for substance abuse and schizophrenia has closed a $20 million Series A round, according to a company statement. The funding will be used to support the launch o... |
| - | 5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M | 5AM Ventures has a stealth new Boston-based startup in the works: Homology Medicines, which is launching with an initial $23 million investment, according to a regulatory filing. It’s being led by 5AM’s managing partner Kush Parmar, the fil... |
| - | Exclusive: 5AM Ventures is raising 2 funds to launch brand new biotech companies | A researcher conducts a breast-cancer-vaccine experiment in a lab at Cleveland Clinic. Shawn Green/Cleveland Clinic This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
5AM Ventures is raising... |
| - | California pharma start-up targeting COPD & asthma using inhalers raises $65M | Redwood City, California-based late-stage start-up Pearl Therapeutics has raised $65 million in a Series D funding round.
The company is developing drugs delivered through an inhaler to tackle respiratory disorders like chronic obstructive ... |
| - | 5AM Ventures raises $119 million for life science, biopharma fund | MENLO PARK, California — California-based 5AM Ventures has raised $119.25 million for its third venture fund, which will close at at least $150 million, according to Venturebeat.
5AM Ventures specializes in seed and early-stage life science... |
| - | Solstice Biologics raises $4M – but where did CEO Lou Tartaglia go? | Looks like Solstice Biologics, the tumultuous San Diego biotech that’s developing some promising RNAi therapeutics, continues its rocky gait – it appears to be sans a CEO.
Through a regulatory filing, we learn it’s just raised a small cache... |
